Partial mTOR inhibition through either pharmacologic or genetic inhibition exerted cardioprotective effects on several subtypes of cardiomyopathies, such as cardiac hypertrophy (Marin et al., 2011; McMullen et al., 2004), lamin A/C-deficient DCM (Ramos et al., 2012), and anemia and doxorubicin-induced cardiomyopathies (DIC) (Ding et al., 2011). Here, MTOR is linked to familial dilated cardiomyopathy.